Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22739
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Clarke, Stephen John | - |
dc.contributor.author | Burge, Matthew | - |
dc.contributor.author | Feeney, Kynan | - |
dc.contributor.author | Gibbs, Peter | - |
dc.contributor.author | Jones, Kristian | - |
dc.contributor.author | Marx, Gavin | - |
dc.contributor.author | Molloy, Mark P | - |
dc.contributor.author | Price, Timothy | - |
dc.contributor.author | Reece, William H H | - |
dc.contributor.author | Segelov, Eva | - |
dc.contributor.author | Tebbutt, Niall C | - |
dc.date | 2020 | - |
dc.date.accessioned | 2020-03-10T22:06:19Z | - |
dc.date.available | 2020-03-10T22:06:19Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | PLoS One 2020; 15(3): e0229900 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/22739 | - |
dc.description.abstract | In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymphocyte ratio (NLR) and treatment outcomes in previously untreated mCRC patients receiving bevacizumab-based therapy has not yet been performed. An open-label, single arm, multi-centre study. Patients received first-line bevacizumab plus XELOX or mFOLFOX6 (Phase-A) and continued bevacizumab plus FOLFIRI beyond first progression (Phase-B). Analyses included the association of NLR with phase A progression free survival (PFS) and overall survival (OS). A sub-study investigated the safety in patients with the primary in situ tumor. An exploratory sub-study examined relationships of circulating proteomic markers with PFS. Phase-A enrolled 128 patients; median age was 64 years (range: 26-84), 70 (55%) were female, 71 (56%) were PS-0 and 51 (40%) had primary in situ tumor. Fifty-three (41%) patients entered Phase-B. The median baseline (b) NLR was 3.2 (range: 1.5-20.4) with 32 (25%) patients having bNLR > 5. The PFS hazard ratio (HR) by bNLR > 5 versus ≤ 5 was 1.4 (95% CI: 0.9-2.2; p = 0.101). The median PFS was 9.2 months (95% CI: 7.9-10.8) for Phase-A and 6.7 months (95% CI: 3.0-8.2) for Phase-B. The HR for OS based on bNLR > 5 versus ≤ 5 was 1.6 (95% CI: 1.0-2.7; p = 0.052). The median OS was 25 months (95% CI: 19.2-29.7) for the full analysis set and 14.9 months for Phase-B. Baseline levels of nine proteomic markers showed a relationship with PFS. Treatment related toxicities were consistent with what has previously been published. There were 4 (3%) instances of GI perforation, of which, 3 (6%) occurred in the primary in situ tumor group. Results from this study are aligned with the previously reported trend towards worse PFS and OS in patients with higher bNLR. ClinicalTrials.gov: NCT01588990; posted May 1, 2012. | - |
dc.language.iso | eng | - |
dc.title | The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | PLoS One | - |
dc.identifier.affiliation | Biostatistics, Covance Pty Ltd, Sydney, Australia | en |
dc.identifier.affiliation | Cancer Services, Royal North Shore Hospital, St Leonards, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Medical Oncology, St Vincent's Hospital, Darlinghurst, Australia | en |
dc.identifier.affiliation | Haematology and Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia | en |
dc.identifier.affiliation | Australian Proteome Analysis Facility, Macquarie University, Sydney, Australia | en |
dc.identifier.affiliation | Integrated Cancer Centre, Sydney Adventist Hospital, and University of Sydney, Wahroonga, Australia | en |
dc.identifier.affiliation | Medical Affairs, Roche Products, Pty, Limited, Sydney, Australia | en |
dc.identifier.affiliation | Medical Oncology, Western Hospital, Footscray, Australia | en |
dc.identifier.affiliation | Department of Oncology, Haematology and Palliative Care, St John of God Murdoch Hospital, Murdoch, Australia | en |
dc.identifier.affiliation | Cancer Care Services, Royal Brisbane and Women Hospital, and University of Queensland, Herston, Australia | en |
dc.identifier.doi | 10.1371/journal.pone.0229900 | - |
dc.identifier.orcid | 0000-0001-5817-1222 | - |
dc.identifier.pubmedid | 32142532 | - |
dc.type.austin | Journal Article | en |
dc.type.austin | Clinical Trial | en |
dc.type.austin | Research Support, Non-U.S. Gov't | en |
local.name.researcher | Tebbutt, Niall C | |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.